2197 — Clover Biopharmaceuticals Share News
0.000.00%
Last trade - 00:00- HK$1.52bn
- HK$1.40bn
- CNY3.51m
China's Clover says its COVID booster shot candidate lifts antibody against Omicron
Brief: Clover’S Covid-19 Vaccine Candidate Demonstrates Strong Cross-Neutralization Against Omicron As A Homologous Booster
Brief: Clover COVID Vaccine Candidate Shows Strong Cross-Neutralization Against Omicron As Homologous Booster
Covid: 19 vaccine scheme for world's poorest pushes for delivery slowdown
Brief: Clover Biopharmaceuticals Doses First Patient With SCB-219M In Phase 1 Trial For Chemotherapy-Induced Thrombocytopenia
Brief: Clover Biopharmaceuticals- Doses 1St Participants In Phase I Trial With Scb-2020S, Potentially Broadly Protective- Chimeric Covid-19 Vaccine Candidate
Brief: Clover Biopharmaceuticals Updates On Bivalent COVID-19 Vaccine Candidate
Brief: Clover Appoints Liongho Chua As President Of Greater China
Brief: Clover Presents Updated Durability And Booster Data For COVID Vaccine Candidate At World Vaccine Congress Washington 2022
Brief: Clover Biopharmaceuticals Posts Loss For Year RMB6.02 Billion
Brief: Clover Biopharmaceuticals Says Co's Covid-19 Vaccine Candidate Demonstrated Durable High Protection Against Omicron As Booster
Brief: Clover’s COVID Vaccine Candidate Demonstrates Durable High Protection, Immune Responses Against Omicron As A Booster
Brief: Clover Biopharmaceuticals Says Shares Will Be Included In Hang Seng Composite Index From March 7
China's Clover to complete COVID-19 booster vaccine development in 2022
Brief: Clover Biopharmaceuticals Plans To Complete Development Of Its Covid-19 Vaccine Candidate As A Universal Covid-19 Booster Vaccine In 2022
Brief: Clover Appoints Nicholas Jackson, Ph.D., As President Of Global Research And Development
Brief: Clover Biopharmaceuticals Updates On Study Of Co's SCB-2019
Brief: Clover Biopharmaceuticals's Unit Enters Collaboration Agreement With Jiangsu Ascentage Pharma
Brief: Clover And Ascentage Pharma Announce Clinical Collaboration